Interleukin-22 and connective tissue diseases: emerging role in pathogenesis and therapy

Interleukin-22 (IL-22), a member of the IL-10 family of cytokines, is produced by a number of immune cells involved in the immune microenvironment of the body. IL-22 plays its pivotal roles by binding to the IL-22 receptor complex (IL-22R) and subsequently activating the IL-22R downstream signalling...

Descripción completa

Detalles Bibliográficos
Autores principales: Xuan, Xiuyun, Zhang, Lin, Tian, Chunxia, Wu, Ting, Ye, Haihua, Cao, Juanmei, Chen, Fangqi, Liang, Yan, Yang, Huilan, Huang, Changzheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788945/
https://www.ncbi.nlm.nih.gov/pubmed/33407883
http://dx.doi.org/10.1186/s13578-020-00504-1
Descripción
Sumario:Interleukin-22 (IL-22), a member of the IL-10 family of cytokines, is produced by a number of immune cells involved in the immune microenvironment of the body. IL-22 plays its pivotal roles by binding to the IL-22 receptor complex (IL-22R) and subsequently activating the IL-22R downstream signalling pathway. It has recently been reported that IL-22 also contributes to the pathogenesis of many connective tissue diseases (CTDs). In this review, we will discuss the role of IL-22 in several CTDs, such as system lupus erythematosus, rheumatoid arthritis, Sjögren’s syndrome, systemic sclerosis and dermatomyositis, suggesting that IL-22 may be a potential therapeutic target in CTDs.

Ejemplares similares